CAJ | 학술논문

目的：评价国际大样本数据库肾透明细胞癌（KIRC）的临床诊治和预后因素。方法选取1998-2012年、国际 TCGA 组织诊断治疗的 KIRC 患者连续病例，分析临床诊疗的特征，评价临床客观疗效和生存时间。结合 lncRNA UCA1基因的表达和相关性分析，评价预后指标。结果共512例 KIRC 入选。女性占35．4％，Ⅰ～Ⅱ期占59．6％，白种人占90．0％，G1～2分级为45．1％。临床诊疗符合指南规范。长链非编码 UCA1（urothelial cancer associated 1）基因表达与 mRNA 亚型、30个基因 mRNA 表达、mir-101-1表达和肿瘤驱动基因 PBRM1的突变具有明显相关性，UCA1高表达组总生存时间明显缩短。结论国际 TCGA-KIRC 研究的诊断治疗符合临床规范，高表达 UCA1是患者重要的不良预后指标，结合其与临床重要驱动基因的相关性，该基因具有明显的进一步研究价值。
목적：평개국제대양본수거고신투명세포암（KIRC）적림상진치화예후인소。방법선취1998-2012년、국제 TCGA 조직진단치료적 KIRC 환자련속병례，분석림상진료적특정，평개림상객관료효화생존시간。결합 lncRNA UCA1기인적표체화상관성분석，평개예후지표。결과공512례 KIRC 입선。녀성점35．4％，Ⅰ～Ⅱ기점59．6％，백충인점90．0％，G1～2분급위45．1％。림상진료부합지남규범。장련비편마 UCA1（urothelial cancer associated 1）기인표체여 mRNA 아형、30개기인 mRNA 표체、mir-101-1표체화종류구동기인 PBRM1적돌변구유명현상관성，UCA1고표체조총생존시간명현축단。결론국제 TCGA-KIRC 연구적진단치료부합림상규범，고표체 UCA1시환자중요적불량예후지표，결합기여림상중요구동기인적상관성，해기인구유명현적진일보연구개치。
Objective To evaluate the clinical diagnosis,treatment and prognostic factors of kidney clear cell renal carcinoma(KIRC)in international sample database.Methods From 1998 to 2012,consecutive patients with KIRC who diagnosed and treated in TCGA organizations were enrolled.Clinical characteristics,objective response and survival time were evaluated,and correlation analysis with lncRNA urothelial cancer associated 1 (UCA1)gene was performed.Results 512 patients with KIRC were enrolled.35.4% of patients were female,59.6% of stage Ⅰ -Ⅱ, 90.0% of white and 45.1% of grade 1 -2.Comprehensive treatment was consistent with the clinical guidelines. Significant correlation was found between UCA1 expression and 4 mRNA subtype,30 genes mRNA expression, mir -101 -1 expression and PBRM1 mutation.And patients with UCA1 overexpression could achieve poor prognosis. Conclusion Diagnosis and treatment of the international TCGA -KIRC research meets clinical guidelines.UCA1 overexpression is an important poor prognostic factor.Combined with the clinical relevance of other important driver genes,UCA1 may be significantly valuable for further study.